SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor Presentation of the Company for the quarter ended 31 March 202325-05-2023
25-05-2023
SHILPA MEDICARE LTD. - 530549 - Board Meeting Outcome for OUTCOME OF THE BOARD MEETING
With reference to the captioned subject we hereby wish to inform you that the Board at its meeting held today i.e., on 25 May 2023 which commenced at 12.30 pm and concluded at 3.30 pm has inter alia considered and approved audited financial results (Standalone and Consolidated) for the quarter and year ended 31 March 202325-05-2023
SHILPA MEDICARE LTD. - 530549 - Approval Of Financial Statements
The audited financial results (Standalone and Consolidated) for the quarter and year ended 31 March 2023, pursuant to Regulation 33 (3) of Listing Regulations. The copy of the same including statement of assets and liabilities, statement of cash flows along with the Auditors'' Report with unmodified opinion and a declaration to the effect that the Auditors have given unmodified opinion on the Audited financial result (Standalone and Consolidated) for the year ended 31 March 202325-05-2023
SHILPA MEDICARE LTD. - 530549 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Pursuant to Regulation 30(2) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we are enclosing herewith the schedule of Q4 & the year ended 31st March 2023 Conference Call to be held on Friday, 26th May 2023 at 01:00 PM IST.25-05-2023
SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare'S New Drug Application For Pemetrexed Injection 1000 Mg/100 Ml, 500 Mg/50 Ml & 100 Mg/10 Ml, Ready To Use Formulation Is Approved By US FDA
This is to inform you that Shilpa Medicare's New Drug Application for Pemetrexed Injection 1000 mg/100 ml, 500 mg/50 ml & 100 mg/10 ml, Ready to Use formulation is approved by US FDA. This is the first NDA product approval received by the Company under 505(b)(2) application, which is a unique formulation supplied as ready to use product solution. This product is required to be administered intravenously without any further dilution. The product is stable at room temperature. The company has developed Pemetrexed formulation as liquid/ ready to use injection against Lyophilized powder formulation of reference ALIMTA(r). The product approval has been received for the application filed from a third party manufacturing site. The Company has already entered into a commercialization agreement with Amneal Pharmaceuticals LLC for the US Market. Pemetrexed injection is used in the treatment of Non-small cell lung cancer & Malignant pleural mesothelioma as approved in the Prescribing Information.23-05-2023
Shilpa Medicare continues to fall despite US FDA relief for Hyderabad unit
This was the second US FDA inspection of the facility, which tests drugs, raw material and packing materials, within a year22-05-2023
SHILPA MEDICARE LTD. - 530549 - Shilpa Medicare Limited, Analytical Services Division (Unit 7, Nacharam, Hyderabad), US FDA GMP Inspection Cleared With VAI Classification
This is to inform you that the US FDA GMP inspection performed on Company's Analytical Services Division situated on first Floor of Unit 7, Nacharam, Hyderabad, Telangana, has been cleared with a status of 'voluntary action indicated (VAI)'. The inspection was held during 08 Mar 2023 to 10 Mar 2023, with issuance of 2 observations. The VAI inspection classification indicates that the US FDA will not take or recommend regulatory or enforcement action because the observations do not meet the threshold for action at this time. The company is committed to ensure continued compliance with cGMP's.22-05-2023
SHILPA MEDICARE LTD. - 530549 - Board Meeting Intimation for Intimation Of Board Meeting Under Regulation 29 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.
SHILPA MEDICARE LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2023 ,inter alia, to consider and approve Pursuant to the provisions of Regulation 29 of Securities Exchange Board of India (Listing Obligations & Disclosure Requirements) Regulations, 2015, we hereby wish to inform you that the Meeting of the Board of Directors of Shilpa Medicare Limited is scheduled on Thursday, 25 May 2023 inter alia to transact the following business items: 1. Approval of the Audited Standalone and Consolidated Financial Results of the Company for the fourth quarter and the financial year ended 31 March 2023 2. Recommendation of Dividend, if any for the financial Year ended 31 March 202317-05-2023
SHILPA MEDICARE LTD. - 530549 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanySHILPA MEDICARE LTD. 2CIN NO.L85110KA1987PLC008739 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 106.00 4Highest Credit Rating during the previous FY A 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)INDIA RATINGS AND RESEARCH PVT. LTD. 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: RITU TIWARY Designation: COMPANY SECRETARY AND COMPLIANCE OFFICER EmailId: CS@VBSHILPA.COM Name of the Chief Financial Officer: ALPESH DALAL Designation: CHIEF FINANCIAL OFFICER EmailId: ALPESHDALAL@VBSHILPA.COM Date: 26/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.26-04-2023